< Back to latest news & events

AGRITECH + IP

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

October 2025

  • Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it?

This case centres on the evidence required to establish “serious doubts” regarding novelty of the well-known Cripps Pink (“Pink Lady”) and Cripps Red (“Sundowner”) apple varieties. As a reminder, novelty of a plant variety right is assessed using a test of “commercial novelty”, rather than a test of “absolute novelty” as used in patent law.

The EU General Court decision (T-159/24) reaffirms that implicit consent to commercialise a plant variety can undermine its EU plant variety right (CPVR) protection.  The Court decided that the supply of varieties to nurseries without clear restrictions as regards their use long before filing the CPVR applications was enough to provide implicit consent to exploit them commercially, to the detriment of their EU plant variety rights.

The takeaway? Even if the intention is merely to hand out new varieties for testing purposes in commercially relevant field trials, it is best to expressly limit the use of new varieties for testing or research purposes to preserve their novelty in a subsequent CPVR application.

The Court also addressed the role of declarations as evidence. It confirmed that declarations may carry weight even without supporting documentation, provided they’re credible, made by impartial parties, and consistent with other evidence.

In short, record-keeping and express limitations regarding commercial uses in contracts are key. Creators of new varieties should document when varieties are disposed of and retain evidence of any use restrictions placed on those varieties to mitigate the possibility of a third party establishing “serious doubts” regarding the novelty of the variety.

Click the button below to read our full article.

Latest updates

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details

Personal names as 'brands' in the world of fashion

Episode 1 Personal names as ‘brands’ in the world of fashion    

Read article

Colour in fashion and the difficulties of protecting it

Episode 2 Colour in fashion and the difficulties of protecting it  

Read article

Trade marks which are fashion products, and fashion products which are trade marks

Episode 3 Trade marks which are fashion products, and fashion products which are trade marks

Read article

Zombie Fashion Brands

Episode 4 Zombie Fashion Brands  

Read article

Trade mark rights protecting fashion designs

Episode 5 Trade mark rights protecting fashion designs

Read article